Si-Qi LYU, Yan-Min YANG, Jun ZHU, Juan WANG, Shuang WU, Jia-Meng REN, Han ZHANG, Xing-Hui SHAO. Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China[J]. Journal of Geriatric Cardiology, 2020, 17(12): 750-758. DOI: 10.11909/j.issn.1671-5411.2020.12.005
Citation: Si-Qi LYU, Yan-Min YANG, Jun ZHU, Juan WANG, Shuang WU, Jia-Meng REN, Han ZHANG, Xing-Hui SHAO. Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China[J]. Journal of Geriatric Cardiology, 2020, 17(12): 750-758. DOI: 10.11909/j.issn.1671-5411.2020.12.005

Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China

  •  Objective To evaluate the effect of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) therapy on the prognosis of patients with atrial fibrillation (AF).
     Methods A total of 1, 991 AF patients from the AF registry were divided into two groups according to whether they were treated with ACEI/ARB at recruitment. Baseline characteristics were carefully collected and analyzed. Logistic regression was utilized to identify the predictors of ACEI/ARB therapy. The primary endpoint was all-cause mortality, while the secondary endpoints included cardiovascular mortality, stroke and major adverse events (MAEs) during the one-year follow-up period. Univariable and multivariable Cox regression were performed to identify the association between ACEI/ARB therapy and the one-year outcomes.
     Results In total, 759 AF patients (38.1%) were treated with ACEI/ARB. Compared with AF patients without ACEI/ARB therapy, patients treated with ACEI/ARB tended to be older and had a higher rate of permanent AF, hypertension, diabetes mellitus, heart failure (HF), left ventricular ejection fraction (LVEF) < 40%, coronary artery disease (CAD), prior myocardial infarction (MI), left ventricular hypertrophy, tobacco use and concomitant medications (all P < 0.05). Hypertension, HF, LVEF < 40%, CAD, prior MI and tobacco use were determined to be predictors of ACEI/ARB treatment. Multivariable analysis showed that ACEI/ARB therapy was associated with a significantly lower risk of one-year all-cause mortality hazard ratio (HR) (95% CI): 0.682 (0.527-0.882), P = 0.003, cardiovascular mortality HR (95% CI): 0.713 (0.514-0.988), P = 0.042 and MAEs HR (95% CI): 0.698 (0.568-0.859), P = 0.001. The association between ACEI/ARB therapy and reduced mortality was consistent in the subgroup analysis.
     Conclusions In patients with AF, ACEI/ARB was related to significantly reduced one-year all-cause mortality, cardiovascular mortality and MAEs despite the high burden of cardiovascular comorbidities.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return